Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Donanemab-azbt (Kisunla)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)FDA safety resources (1)

Review note before using historical content

Kisunla historical titration is superseded

The restored article uses the original 2024 titration schedule. The U.S. label subsequently changed the initiating titration to reduce ARIA-related risk. Do not use the historical dose-escalation schedule; consult current Dosing Instructions, section 2.2, and the associated ARIA monitoring requirements.

Safety sources and review scope
  • Kisunla U.S. prescribing information (opens in a new tab)Source URL: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=190352d4-ef62-4679-b4fa-e846e2766afa

    Exact location: 2.2 Dosing Instructions, Table 1; UUID 9f16fe61-1a15-4ec1-8214-88a48341db05; 5.1 ARIA, Dosing Regimen 2 discussion

    Source family: Kisunla U.S. prescribing information

    Scope: SPL version8 effective2025-12-30, printed revision07/2025. Exact-stocked-product reconciliation and whole-monograph review remain pending.

  • Kisunla U.S. prescribing information (opens in a new tab)Source URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761248s004lbl.pdf

    Exact location: 2.2 Dosing Instructions, Table1; 5.1 Amyloid Related Imaging Abnormalities; 14 Clinical Studies, Study2

    Source family: Kisunla U.S. prescribing information

    Scope: FDA-approved label reproduction of the same label family, not independent clinical corroboration.

Historical source in disagreement: Archived GlobalRPh article (opens in a new tab)Historical source URL: https://globalrph.com/dilution/kisunla-donanemab-azbt/

Historical location: Revised7/2024; DOSAGE AND ADMINISTRATION2.2 Dosing Instructions

Review-note ID: H62-SAFETY-KISUNLA-TITRATION. The historical source remains preserved; this note does not qualify its complete monograph.

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

KISUNLA - donanemab-azbt (opens in a new tab)Original source URL: https://globalrph.com/dilution/kisunla-donanemab-azbt/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/kisunla-donanemab-azbt/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:51:26.860333+00:00
Source location
div.post-content
Packaged content SHA-256
7ee6d6ce29436b888ebb43496d15f447dfdebc497bf0074787265fc8769455c7
Original response SHA-256
cb46f13b7c65060633289b6698bb32175da2405d3976cc1cce3d54f53ab54895
Source body SHA-256
d0b8e485f120348ecd5826125b0901e39343d77b0affc00fc62a7d6c528f9d9e

KISUNLATM (donanemab-azbt) injection

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information (pdf)]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

Kisunla historical titration is superseded

The restored article uses the original 2024 titration schedule. The U.S. label subsequently changed the initiating titration to reduce ARIA-related risk. Do not use the historical dose-escalation schedule; consult current Dosing Instructions, section 2.2, and the associated ARIA monitoring requirements.

Current-source reference: 2.2 Dosing Instructions, Table 1; UUID 9f16fe61-1a15-4ec1-8214-88a48341db05; 5.1 ARIA, Dosing Regimen 2 discussion

Current-source reference: 2.2 Dosing Instructions, Table1; 5.1 Amyloid Related Imaging Abnormalities; 14 Clinical Studies, Study2

[ Final solution: 4 to 10 mg/mL] [30 minutes]
See below. Also Dosage and Administration.

Dilution Instructions

  • Prior to administration, KISUNLA must be diluted with 0.9% sodium chloride injection (see Table 4).
  • Use aseptic technique when preparing the diluted KISUNLA solution for intravenous infusion.
  • Allow KISUNLA to equilibrate to room temperature before preparation.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. KISUNLA solution is clear to opalescent, colorless to slightly yellow to slightly brown. Do not use if particulate matter or discolorations are present.
  • Withdraw required volume of KISUNLA and mix with 0.9% sodium chloride injection, to the recommended total volume for a final concentration of 4 mg/mL to 10 mg/mL (see Table 4). Use only 0.9% sodium chloride injection for dilution.
Table 4: Preparation and Reconstitution of KISUNLA
KISUNLA Dose (mg) KISUNLA Volume (mL) Volume of 0.9% Sodium Chloride Injection Diluent (mL) Final Volume of Diluted Solution to be Infused (mL) Final Concentration of Diluted Solution (mg/mL)a
700 mg 40 mLb 30 mL to 135 mL 70 mL to 175 mL 700 mg/175 mL (4 mg/mL) to 700 mg/70 mL (10 mg/mL)
1400 mg 80 mLc 60 mL to 270 mL 140 mL to 350 mL 1400 mg/350 mL (4 mg/mL) to 1400 mg/140 mL (10 mg/mL)

a. final concentration of 4 mg/mL to 10 mg/mL

b. 2 vials of KISUNLA

c. 4 vials of KISUNLA

Administration Instructions

  • Visually inspect the diluted KISUNLA solution for particles or discoloration prior to administration. Do not use if it is discolored, or opaque or foreign particles are seen.
  • Prior to infusion, if the diluted solution has been stored under refrigeration, allow the diluted KISUNLA solution to warm to room temperature.
  • Administer the entire diluted solution intravenously over approximately 30 minutes.
  • Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity-type reaction [see Warnings and Precautions (5.2)].
  • Flush the line only with 0.9% sodium chloride injection at the end of the infusion per access specific line maintenance protocol.
  • Observe the patient post-infusion for a minimum of 30 minutes to evaluate for infusion reactions and hypersensitivity reactions

Storage and stability:

Unopened Vial

  • Store refrigerated at 2°C to 8°C (36°F to 46°F).
  • Keep the vial in the outer carton to protect from light.
  • Do not freeze or shake.
  • If refrigeration is not available, may be stored at room temperature (20°C to 25°C [68°F to 77°F]) for up to 3 days.

Diluted Solution

  • Each vial is for one-time use only. Discard any unused portion left in the vial.
  • Gently invert the diluted KISUNLA solution to mix completely. Do not shake.
  • After dilution, immediate use is recommended [see Description (11)]. If the diluted KISUNLA solution is not administered immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) for up to 72 hours or at room temperature (20°C to 25°C [68°F to 77°F]) for up to 12 hours.
  • Do not freeze the diluted KISUNLA solution.
  • Storage times include the duration of infusion.

See warnings and precautions below.
WARNING:
WARNING: AMYLOID RELATED IMAGING ABNORMALITIES
See full prescribing information for complete boxed warning.
Monoclonal antibodies directed against aggregated forms of beta amyloid, including KISUNLA, can cause amyloid related imaging abnormalities (ARIA), as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). ARIA is usually asymptomatic, although serious and life-threatening events can rarely occur. Serious intracerebral hemorrhages >1 cm have occurred in patients treated with this class of medications. ARIA-E can cause focal neurologic deficits that can mimic ischemic stroke. (5.1, 6.1)

ApoE ε4 Homozygotes

Patients treated with this class of medications, including KISUNLA, who are ApoE ε4 homozygotes have a higher incidence of ARIA, including symptomatic and serious ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. (5.1)

Consider the benefit for the treatment of Alzheimer's disease and risk of ARIA when deciding to treat with KISUNLA. (5.1, 14) Drug information (pdf)

Description: Donanemab-azbt is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta, and is expressed in a Chinese hamster ovary cell line. Donanemab-azbt has an approximate molecular weight of 145 kDa.

KISUNLA (donanemab-azbt) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow to slightly brown solution for intravenous infusion after dilution. KISUNLA is supplied in single-dose vials available in a concentration of 350 mg/20 mL (17.5 mg/mL).

Each mL of solution contains 17.5 mg donanemab-azbt, anhydrous citric acid (0.32 mg), polysorbate 80 (0.20 mg), sodium citrate (2.15 mg), sucrose (80 mg), and Water for Injection, USP, at a pH of 5.5 to 6.5.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:
Donanemab-azbt is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. Donanemab-azbt reduces amyloid beta plaques, as evaluated in Study

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:
KISUNLATM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials.

CONTRAINDICATIONS Return to article top

Contraindications:

KISUNLA is contraindicated in patients with known serious hypersensitivity to donanemab-azbt or to any of the excipients.

WARNINGS AND PRECAUTIONS:
  • Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 24 weeks of treatment with KISUNLA. Risk of ARIA, including symptomatic ARIA, was increased in apolipoprotein E ε4 (ApoE ε4) homozygotes compared to heterozygotes and noncarriers. The risk of ARIA-E and ARIA-H is increased in KISUNLA-treated patients with pretreatment microhemorrhages and/or superficial siderosis. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including MRI scanning if indicated. (2.3, 5.1)
  • Infusion-Related Reactions: The infusion rate may be reduced, or the infusion may be discontinued, and appropriate therapy initiated as clinically indicated. Consider pre-treatment with antihistamines, acetaminophen, or corticosteroids prior to subsequent dosing. (5.3)Drug information (pdf)

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:
Most common adverse reactions (at least 10% and higher incidence compared to placebo): ARIA-E, ARIA-H microhemorrhage, ARIA-H superficial siderosis, and headache. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
Drug information (pdf)
Revised: 7/2024

DOSAGE AND ADMINISTRATION Return to article top

Kisunla historical titration is superseded

The restored article uses the original 2024 titration schedule. The U.S. label subsequently changed the initiating titration to reduce ARIA-related risk. Do not use the historical dose-escalation schedule; consult current Dosing Instructions, section 2.2, and the associated ARIA monitoring requirements.

Current-source reference: 2.2 Dosing Instructions, Table 1; UUID 9f16fe61-1a15-4ec1-8214-88a48341db05; 5.1 ARIA, Dosing Regimen 2 discussion

Current-source reference: 2.2 Dosing Instructions, Table1; 5.1 Amyloid Related Imaging Abnormalities; 14 Clinical Studies, Study2

DOSAGE AND ADMINISTRATION:

2.1 Patient Selection
Confirm the presence of amyloid beta pathology prior to initiating treatment [see Clinical Pharmacology Drug information (pdf)]

2.2 Dosing Instructions

The recommended dosage of KISUNLA is 700 mg every four weeks for three doses, then 1400 mg every four weeks (see Table 1). KISUNLA is administered every four weeks as an intravenous infusion over approximately 30 minutes. KISUNLA must be diluted prior to administration (see Table 4).

Table 1: Dosing Schedule
Intravenous Infusion
(every 4 weeks)		 KISUNLA Dosage
(administered over approximately 30 minutes)
Infusions 1, 2, and 3 700 mg
Infusion 4 and beyond 1400 mg

Consider stopping dosing with KISUNLA based on reduction of amyloid plaques to minimal levels on amyloid PET imaging. In Study 1, dosing was stopped based on a reduction of amyloid levels below predefined thresholds on PET imaging [see Clinical Studies (14) Drug information (pdf)].

If an infusion is missed, resume administration every 4 weeks at the same dose as soon as possible.

2.3 Monitoring and Dosing Interruption for Amyloid Related Imaging Abnormalities

KISUNLA can cause amyloid related imaging abnormalities -edema (ARIA-E) and -hemosiderin deposition (ARIA-H) [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

Monitoring for ARIA

Obtain a recent baseline brain magnetic resonance imaging (MRI) prior to initiating treatment with KISUNLA. Obtain an MRI prior to the 2nd, 3rd, 4th, and 7th infusions. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including an MRI if indicated.

Recommendations for Dosing Interruptions in Patients with ARIA

ARIA-E

The recommendations for dosing interruptions for patients with ARIA-E are provided in Table 2.

Clinical Symptom Severitya ARIA-E Severity on MRI
Mild Moderate Severe
Asymptomatic May continue dosing at current dose and schedule Suspend dosingb Suspend dosingb
Mild May continue dosing based on clinical judgment Suspend dosingb
Moderate or Severe Suspend dosingb

a. Mild: discomfort noticed, but no disruption of normal daily activity.
Moderate: discomfort sufficient to reduce or affect normal daily activity.
Severe: incapacitating, with inability to work or to perform normal daily activity.

b. Suspend until MRI demonstrates radiographic resolution and symptoms, if present, resolve; consider a follow-up MRI to assess for resolution 2 to 4 months after initial identification. Resumption of dosing should be guided by clinical judgment.

ARIA-H
The recommendations for dosing interruptions for patients with ARIA-H are provided in Table 3.

Table 3: Dosing Recommendations for Patients With ARIA-H

Clinical Symptom Severity ARIA-H Severity on MRI
Mild Moderate Severe
Asymptomatic May continue dosing at current dose and schedule Suspend dosinga Suspend dosingb
Symptomatic Suspend dosinga Suspend dosinga

a. Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; resumption of dosing should be guided by clinical judgment; consider a follow-up MRI to assess for stabilization 2 to 4 months after initial identification.

b. Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve. Use clinical judgment when considering whether to continue treatment or permanently discontinue KISUNLA.

In patients who develop intracerebral hemorrhage greater than 1 cm in diameter during treatment with KISUNLA, suspend dosing until MRI demonstrates radiographic stabilization and symptoms, if present, resolve. Resumption of dosing should be guided by clinical judgment.

2.4 Dilution Instructions

  • Prior to administration, KISUNLA must be diluted with 0.9% sodium chloride injection (see Table 4).
  • Use aseptic technique when preparing the diluted KISUNLA solution for intravenous infusion.
  • Allow KISUNLA to equilibrate to room temperature before preparation.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. KISUNLA solution is clear to opalescent, colorless to slightly yellow to slightly brown. Do not use if particulate matter or discolorations are present.
  • Withdraw required volume of KISUNLA and mix with 0.9% sodium chloride injection, to the recommended total volume for a final concentration of 4 mg/mL to 10 mg/mL (see Table 4). Use only 0.9% sodium chloride injection for dilution.
Table 4: Preparation and Reconstitution of KISUNLA
KISUNLA Dose (mg) KISUNLA Volume (mL) Volume of 0.9% Sodium Chloride Injection Diluent (mL) Final Volume of Diluted Solution to be Infused (mL) Final Concentration of Diluted Solution (mg/mL)a
700 mg 40 mLb 30 mL to 135 mL 70 mL to 175 mL 700 mg/175 mL (4 mg/mL) to 700 mg/70 mL (10 mg/mL)
1400 mg 80 mLc 60 mL to 270 mL 140 mL to 350 mL 1400 mg/350 mL (4 mg/mL) to 1400 mg/140 mL (10 mg/mL)

a. final concentration of 4 mg/mL to 10 mg/mL

b. 2 vials of KISUNLA

c. 4 vials of KISUNLA

  • Each vial is for one-time use only. Discard any unused portion left in the vial.
  • Gently invert the diluted KISUNLA solution to mix completely. Do not shake.
  • After dilution, immediate use is recommended [see Description (11)]. If the diluted KISUNLA solution is not administered immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) for up to 72 hours or at room temperature (20°C to 25°C [68°F to 77°F]) for up to 12 hours.
  • Do not freeze the diluted KISUNLA solution.
  • Storage times include the duration of infusion.

2.5 Administration Instructions

  • Visually inspect the diluted KISUNLA solution for particles or discoloration prior to administration. Do not use if it is discolored, or opaque or foreign particles are seen.
  • Prior to infusion, if the diluted solution has been stored under refrigeration, allow the diluted KISUNLA solution to warm to room temperature.
  • Administer the entire diluted solution intravenously over approximately 30 minutes.
  • Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity-type reaction [see Warnings and Precautions (5.2)].
  • Flush the line only with 0.9% sodium chloride injection at the end of the infusion per access specific line maintenance protocol.
  • Observe the patient post-infusion for a minimum of 30 minutes to evaluate for infusion reactions and hypersensitivity reactions [see Warnings and Precautions (5.2)].

DOSAGE FORMS AND STRENGTHS:
KISUNLA (donanemab-azbt) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow to slightly brown solution. KISUNLA is supplied in one vial per carton as follows:

350 mg/20 mL (17.5 mg/mL) single-dose vial: NDC 0002-9401-01.

Storage and Stability Return to article top

Unopened Vial

  • Store refrigerated at 2°C to 8°C (36°F to 46°F).
  • Keep the vial in the outer carton to protect from light.
  • Do not freeze or shake.
  • If refrigeration is not available, may be stored at room temperature (20°C to 25°C [68°F to 77°F]) for up to 3 days.

Diluted Solution

  • Each vial is for one-time use only. Discard any unused portion left in the vial.
  • Gently invert the diluted KISUNLA solution to mix completely. Do not shake.
  • After dilution, immediate use is recommended [see Description (11)]. If the diluted KISUNLA solution is not administered immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) for up to 72 hours or at room temperature (20°C to 25°C [68°F to 77°F]) for up to 12 hours.
  • Do not freeze the diluted KISUNLA solution.
  • Storage times include the duration of infusion.

Open this historical article on its own

FDA safety resources for this medication (1)

Read the linked communication and current prescribing information before use. Resource dates and affected product scopes differ; a listed resource is not a full monograph or a lot-specific clearance.

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      donanemab-azbt-kisunla
      Source IDH51-6C1BA14C4B35127EF4F285CA
      Generic name
      Donanemab-azbt (Kisunla)
      Source IDH51-DA6DA70BAF604A4BC4C56150
      Class
      Biologics and immunotherapy
      Source IDH51-8DA12D22B8AAE6C62D6E1CAE
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-D9F98655C68C052E2FA77F88
      Primary uses
      1. The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic.
        Source IDH51-8011520BCF267962393F90AB
      Mechanism
      Binds pyroglutamate-modified aggregated amyloid beta and promotes plaque clearance.
      Source IDH51-42CAA8B634E47B91C021009C
      Mechanism level
      drug_specific
      Source IDH51-2FBA4E04D48CA8E072B22F7A
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-0EC9F7547C8F6EE9E41B700A
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-FE8E90C51CFAB1235A105A0A
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-11C56B6B7211A81B5E66871A
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-51028CA32A636078E94A4BD4
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-1C15B744B1C9C20D51461DA4
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-CD55E2721394381DC2E4F67D
      Legacy title
      Donanemab-azbt (Kisunla)
      Source IDH51-C5B29943AC40B64C8470DF15
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-0C4FE862D7A9FDC1CBE75B49
      Search text
      Donanemab-azbt (Kisunla) Biologics and immunotherapy Legacy GlobalRPh directory entry The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic. Binds pyroglutamate-modified aggregated amyloid beta and promotes plaque clearance. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-DA7BE00C77A2D90F642FE616
      Official access mode
      none
      Source IDH51-C0345813543A601770606B01
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-2C7257389A700BE818B2EBA2

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-FEA298710852D38C10EF4014
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-DFCA13D3D03CC9C6FDDB58A4
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-1C81FFA9AAAA8E6D4C0918C3

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-509975164DF5DB5997616C50

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-25D4D97E27389DB43CD2A9B0
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      donanemab-azbt-kisunla
      Source IDH51-EB0F2B0213584F71523026DC
      Legacy title
      Donanemab-azbt (Kisunla)
      Source IDH51-4BC2FC60C49F3F5014F0DB57
      Generic name
      Donanemab-azbt (Kisunla)
      Source IDH51-7B9F574F8663C49AC27F41E4
      Class
      Biologics and immunotherapy
      Source IDH51-64A23BEDB62ECA72B6A6344F
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-36E2D58B90CF492A17DDCEE8
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-A24BF93D1E2B6B9388024D15
      Populations
      1. Population not yet normalized
        Source IDH51-D09CE5B20B10A4A09D6DC7A7
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-523EA8C536BC9ED953B50807
      High alert
      false
      Source IDH51-B915E948A88A2A36C9CDA334
      Hazardous
      false
      Source IDH51-3ACD059A43692E85AEEA0E60
      Status
      Legacy migration
      Source IDH51-E31942AC1D29D72DC4FD65D1
      Version added
      Legacy
      Source IDH51-3477186E9543ED3F2588C552
      Sources
      LabelUrlKind
      Source IDH51-8B5632BBF8FCE6F458E42B73
      GlobalRPh legacy IV dilution monograph
      Source IDH51-7FFCA51E17E518B41BC1F66C
      		legacy:auto
      Source IDH51-8601FD622F9211FA0782AD56
      		Legacy
      Source IDH51-BD4BBC73F437710E92EB2A08
      Clinical release verification
      Audit version
      3.4
      Source IDH51-B134D83A9C2538FEDE9B3191
      Audited on
      2026-08-30
      Source IDH51-D2822BB97D4308DC1364C056
      Level
      red
      Source IDH51-BDD26AE3ADCF3DB2452EBBBA
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-2172A5A345DAC94BB23A19FF
      Exact current label candidate
      false
      Source IDH51-9C83E69AD49B699409B97E83
      Reference url count
      0
      Source IDH51-290A433FDD7C48DFF1D62D90
      Broken reference count
      0
      Source IDH51-2F073AA9F96F7A21604F2618
      Point of use confirmation required
      true
      Source IDH51-CE582B0B89C37D9B10C8813B
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-D0EBDC39F54A7E23553FE362

      Dosing source fields

      Id
      donanemab-azbt-kisunla
      Source IDH51-65F2A511C5AAB55ACD947AAA
      Generic name
      Donanemab-azbt (Kisunla)
      Source IDH51-328F224948EB38F4EC34D318
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-5328BE05E7CFC3E3A66C5CCF
      Package insert
      Query name
      Donanemab-azbt
      Source IDH51-9045D86D5A2B1DE138E2D9FE
      Product and route must match
      true
      Source IDH51-357997FEF124FA3B5A62DA53
      Live current label enabled
      false
      Source IDH51-6C6EFDD44827F6DF37E7A53C
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-B80148DA049B0D8FC7263E2C
      Direct official label access enabled
      true
      Source IDH51-6921ECD8F0E76B2CA36EDB83
      Outbound server request required
      false
      Source IDH51-6976FCED12500C290472F876
      Local summary status
      not_bundled
      Source IDH51-D70B0EFEC17DC9570E1E6FA1
      Clinical review
      Locally normalized
      false
      Source IDH51-4864C47894DCFBA4C433BECE
      Reviewed
      2026-08-29
      Source IDH51-EED93CC1051688A2CA6A8CC4
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-5B9D3218049149B7375A7966
      Clinical release verification
      Audit version
      3.4
      Source IDH51-767431835319090E345C2201
      Audited on
      2026-08-30
      Source IDH51-21EB7012414F711D5D62ACAB
      Level
      red
      Source IDH51-E17FE7BA9B216585F3093CBF
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-F15A2A5ACB46C256FC30F061
      Exact current label candidate
      false
      Source IDH51-6A5AF85EF8EC377C942276F5
      Reference url count
      0
      Source IDH51-FB4E90CDDC0215B2A3FB6E90
      Broken reference count
      0
      Source IDH51-A4EAE42D7B8F556493846E8C
      Point of use confirmation required
      true
      Source IDH51-143E01E009B5B35C4F3A807E
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-A2ADD18ABB66C69492ED1488
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      donanemab-azbt-kisunla
      Source IDH51-C874E8DD78BE60E6AC04206C
      Name
      Donanemab-azbt (Kisunla)
      Source IDH51-7693F1AA3E7A8C55F18CBB37
      Therapeutic class
      Biologics and immunotherapy
      Source IDH51-6ADC0E8B387E7C0EC04F67AA
      Review version
      3.1
      Source IDH51-C854314174264D01351E93AF
      Review date
      2026-08-30
      Source IDH51-56B4EFCCB97A64755BED20DD
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-C2B1876C9DDC0ED96CC15606
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-C15F8B9DC8DC7F13B9B875C1
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-CC9338E168AFDB726F9EFE34
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-79C461C7FDBFBFCC803E3E2F
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-D415A7D34C531471B554B33E
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-C0EF4D2FFE697E8FBF545D13
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-5C4496279CE362CD9152F5AF
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-923BE927886007FDA20AECAA
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-FCE8431F77476A07603AC219
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-AAD68AF1922069E54ED7F12C
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-2F2ECC7F2B5774B615471AFA
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-2FDE06ACDB7227D7C84A0FBD
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-550EED751EA0ED17D8158894
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-29243931C76AA0E06BBD63BF
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-018854A1832C33006D6EC7E8
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-7904A78EB51A4D58B1A6D66E
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-D06280C65333C4A19CB0EF0F
      Adult dosing range
      Primary
      not_found
      Source IDH51-A42FAFAC6BDB6F66D4BC160E
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-536480C5B860FF9D306D926F
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-B3B4CBD0C03D72913E3E424B
      Infusion time
      Primary
      not_found
      Source IDH51-0484553FEC8ED39E504835E0
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-E9C685B019A5EC75F99501EE
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-770931D8C0FA0C41AB54145C
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-A97356075F2EB8EEE0D3D3D7
      Guide generation allowed
      false
      Source IDH51-69945699737EFD769FC3D49C
      Pediatric
      Applicability
      not_established
      Source IDH51-DAA9FC1B3DB5439D95374BED
      Guide generation allowed
      false
      Source IDH51-FE41037F7B055BD2C3572708
      Neonatal
      Applicability
      not_established
      Source IDH51-54DE6F8F6D11060778B253F0
      Guide generation allowed
      false
      Source IDH51-6E30F75BE94E6FA679CFE3C7
      Route presence
      Structured dilution
      false
      Source IDH51-C41A5EAF3AF4BF73D2E1056B
      Iv push
      false
      Source IDH51-7B8E11D0EA032EEC204D43D6
      Continuous infusion
      false
      Source IDH51-9BBB16735E5FC5B42008B976
      Pediatric source
      false
      Source IDH51-41AB8FCDFD8C68CD91FA4796
      Neonatal source
      false
      Source IDH51-3527F93E8BABA1A716D40C97
      Legacy reference
      Status
      not_available
      Source IDH51-7E93CDCF55AAD06866FE070C
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-21583C1717AEC992EFDD0B18
      Source files
      1. catalog.json
        Source IDH51-42817FEFF23E053234E4F9A9
      2. dosing.json
        Source IDH51-23A141B29332816DD717E52B
      3. legacy-map.json
        Source IDH51-A26C9FE66FD0307CAE131B53
      4. review-queue.json
        Source IDH51-FFCEC7BF756F62443CF1956A
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-5FE0050948C02126A5D77558
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-EB0F2B0213584F71523026DCcatalog.json
      /records/83/id      		Historical; current review incomplete
      H51-4BC2FC60C49F3F5014F0DB57catalog.json
      /records/83/legacy_title      		Historical; current review incomplete
      H51-7B9F574F8663C49AC27F41E4catalog.json
      /records/83/generic_name      		Historical; current review incomplete
      H51-64A23BEDB62ECA72B6A6344Fcatalog.json
      /records/83/class      		Historical; current review incomplete
      H51-36E2D58B90CF492A17DDCEE8catalog.json
      /records/83/subclass      		Historical; current review incomplete
      H51-A24BF93D1E2B6B9388024D15catalog.json
      /records/83/summary      		Historical; current review incomplete
      H51-509975164DF5DB5997616C50catalog.json
      /records/83/warnings/0      		Historical; current review incomplete
      H51-25D4D97E27389DB43CD2A9B0catalog.json
      /records/83/stability_notes/0      		Historical; current review incomplete
      H51-D09CE5B20B10A4A09D6DC7A7catalog.json
      /records/83/populations/0      		Historical; current review incomplete
      H51-523EA8C536BC9ED953B50807catalog.json
      /records/83/evidence_tier      		Historical; current review incomplete
      H51-B915E948A88A2A36C9CDA334catalog.json
      /records/83/high_alert      		Historical; current review incomplete
      H51-3ACD059A43692E85AEEA0E60catalog.json
      /records/83/hazardous      		Historical; current review incomplete
      H51-E31942AC1D29D72DC4FD65D1catalog.json
      /records/83/status      		Historical; current review incomplete
      H51-04BE2F0C3EB8F59ABC0A55EBcatalog.json
      /records/83/reviewed      		Historical; current review incomplete
      H51-3477186E9543ED3F2588C552catalog.json
      /records/83/version_added      		Historical; current review incomplete
      H51-8B5632BBF8FCE6F458E42B73catalog.json
      /records/83/sources/0      		Historical; current review incomplete
      H51-7FFCA51E17E518B41BC1F66Ccatalog.json
      /records/83/sources/0/label      		Historical; current review incomplete
      H51-8601FD622F9211FA0782AD56catalog.json
      /records/83/sources/0/url      		Historical; current review incomplete
      H51-BD4BBC73F437710E92EB2A08catalog.json
      /records/83/sources/0/kind      		Historical; current review incomplete
      H51-B134D83A9C2538FEDE9B3191catalog.json
      /records/83/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-D2822BB97D4308DC1364C056catalog.json
      /records/83/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-BDD26AE3ADCF3DB2452EBBBAcatalog.json
      /records/83/clinical_release_verification/level      		Historical; current review incomplete
      H51-2172A5A345DAC94BB23A19FFcatalog.json
      /records/83/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-9C83E69AD49B699409B97E83catalog.json
      /records/83/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-FEB735774438F6CD5F09369Dcatalog.json
      /records/83/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-5C80803DB68C8E25CD867AB7catalog.json
      /records/83/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-07C0636EA37A0E16428F709Bcatalog.json
      /records/83/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-290A433FDD7C48DFF1D62D90catalog.json
      /records/83/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-2F073AA9F96F7A21604F2618catalog.json
      /records/83/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-CE582B0B89C37D9B10C8813Bcatalog.json
      /records/83/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-D0EBDC39F54A7E23553FE362catalog.json
      /records/83/clinical_release_verification/note      		Historical; current review incomplete
      H51-3FDF686F8F8D010097EB5B7Bcatalog.json
      /records/83/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-65F2A511C5AAB55ACD947AAAdosing.json
      /records/83/id      		Historical; current review incomplete
      H51-328F224948EB38F4EC34D318dosing.json
      /records/83/generic_name      		Historical; current review incomplete
      H51-5328BE05E7CFC3E3A66C5CCFdosing.json
      /records/83/coverage_status      		Historical; current review incomplete
      H51-9045D86D5A2B1DE138E2D9FEdosing.json
      /records/83/package_insert/query_name      		Historical; current review incomplete
      H51-CD83D81F3EFBADD798A2D96Ddosing.json
      /records/83/package_insert/preferred_setid      		Historical; current review incomplete
      H51-357997FEF124FA3B5A62DA53dosing.json
      /records/83/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-6C6EFDD44827F6DF37E7A53Cdosing.json
      /records/83/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-B80148DA049B0D8FC7263E2Cdosing.json
      /records/83/package_insert/source_priority      		Historical; current review incomplete
      H51-6921ECD8F0E76B2CA36EDB83dosing.json
      /records/83/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-6976FCED12500C290472F876dosing.json
      /records/83/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-D70B0EFEC17DC9570E1E6FA1dosing.json
      /records/83/package_insert/local_summary_status      		Historical; current review incomplete
      H51-FEA298710852D38C10EF4014dosing.json
      /records/83/renal/classification      		Historical; current review incomplete
      H51-DFCA13D3D03CC9C6FDDB58A4dosing.json
      /records/83/renal/summary      		Historical; current review incomplete
      H51-1C81FFA9AAAA8E6D4C0918C3dosing.json
      /records/83/renal/method_note      		Historical; current review incomplete
      H51-4864C47894DCFBA4C433BECEdosing.json
      /records/83/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-EED93CC1051688A2CA6A8CC4dosing.json
      /records/83/clinical_review/reviewed      		Historical; current review incomplete
      H51-5B9D3218049149B7375A7966dosing.json
      /records/83/clinical_review/status      		Historical; current review incomplete
      H51-767431835319090E345C2201dosing.json
      /records/83/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-21EB7012414F711D5D62ACABdosing.json
      /records/83/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-E17FE7BA9B216585F3093CBFdosing.json
      /records/83/clinical_release_verification/level      		Historical; current review incomplete
      H51-F15A2A5ACB46C256FC30F061dosing.json
      /records/83/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-6A5AF85EF8EC377C942276F5dosing.json
      /records/83/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-027BA65C5B9D687C1F79E25Fdosing.json
      /records/83/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-106BDE103742D05388CAB4E2dosing.json
      /records/83/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-8D1EECD0027ADC5391EE2619dosing.json
      /records/83/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-FB4E90CDDC0215B2A3FB6E90dosing.json
      /records/83/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-A4EAE42D7B8F556493846E8Cdosing.json
      /records/83/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-143E01E009B5B35C4F3A807Edosing.json
      /records/83/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-A2ADD18ABB66C69492ED1488dosing.json
      /records/83/clinical_release_verification/note      		Historical; current review incomplete
      H51-2C1342640F0E3B22AA6E5260dosing.json
      /records/83/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-6C1BA14C4B35127EF4F285CAfirst-look-v5.1.json
      /records/83/id      		Historical; current review incomplete
      H51-DA6DA70BAF604A4BC4C56150first-look-v5.1.json
      /records/83/generic_name      		Historical; current review incomplete
      H51-8DA12D22B8AAE6C62D6E1CAEfirst-look-v5.1.json
      /records/83/class      		Historical; current review incomplete
      H51-D9F98655C68C052E2FA77F88first-look-v5.1.json
      /records/83/subclass      		Historical; current review incomplete
      H51-8011520BCF267962393F90ABfirst-look-v5.1.json
      /records/83/primary_uses/0      		Historical; current review incomplete
      H51-42CAA8B634E47B91C021009Cfirst-look-v5.1.json
      /records/83/mechanism      		Historical; current review incomplete
      H51-2FBA4E04D48CA8E072B22F7Afirst-look-v5.1.json
      /records/83/mechanism_level      		Historical; current review incomplete
      H51-0EC9F7547C8F6EE9E41B700Afirst-look-v5.1.json
      /records/83/basic_dosing_orientation      		Historical; current review incomplete
      H51-FE8E90C51CFAB1235A105A0Afirst-look-v5.1.json
      /records/83/administration_orientation      		Historical; current review incomplete
      H51-11C56B6B7211A81B5E66871Afirst-look-v5.1.json
      /records/83/renal_and_population_orientation      		Historical; current review incomplete
      H51-51028CA32A636078E94A4BD4first-look-v5.1.json
      /records/83/key_safety_orientation/0      		Historical; current review incomplete
      H51-1C15B744B1C9C20D51461DA4first-look-v5.1.json
      /records/83/coverage_path      		Historical; current review incomplete
      H51-CD55E2721394381DC2E4F67Dfirst-look-v5.1.json
      /records/83/coverage_path_label      		Historical; current review incomplete
      H51-BAC8940CC48DA572DFA3CC1Afirst-look-v5.1.json
      /records/83/official_label_url      		Historical; current review incomplete
      H51-C5B29943AC40B64C8470DF15first-look-v5.1.json
      /records/83/legacy_title      		Historical; current review incomplete
      H51-0C4FE862D7A9FDC1CBE75B49first-look-v5.1.json
      /records/83/review_note      		Historical; current review incomplete
      H51-DA7BE00C77A2D90F642FE616first-look-v5.1.json
      /records/83/search_text      		Historical; current review incomplete
      H51-FE20826F525DE5463496AAA6first-look-v5.1.json
      /records/83/official_search_url      		Historical; current review incomplete
      H51-C0345813543A601770606B01first-look-v5.1.json
      /records/83/official_access_mode      		Historical; current review incomplete
      H51-D3E43279AC443F241CF92F42first-look-v5.1.json
      /records/83/official_access_url      		Historical; current review incomplete
      H51-F67B691576FA2FAD98FD46BCfirst-look-v5.1.json
      /records/83/official_search_query      		Historical; current review incomplete
      H51-2C7257389A700BE818B2EBA2first-look-v5.1.json
      /records/83/official_access_reason      		Historical; current review incomplete
      H51-C874E8DD78BE60E6AC04206Cpreparation-assessments-v3.8.json
      /83/id      		Historical; current review incomplete
      H51-7693F1AA3E7A8C55F18CBB37preparation-assessments-v3.8.json
      /83/name      		Historical; current review incomplete
      H51-E75D1B437A0FBA282602D854preparation-assessments-v3.8.json
      /83/brands      		Historical; current review incomplete
      H51-6ADC0E8B387E7C0EC04F67AApreparation-assessments-v3.8.json
      /83/therapeutic_class      		Historical; current review incomplete
      H51-C854314174264D01351E93AFpreparation-assessments-v3.8.json
      /83/review_version      		Historical; current review incomplete
      H51-56B4EFCCB97A64755BED20DDpreparation-assessments-v3.8.json
      /83/review_date      		Historical; current review incomplete
      H51-C2B1876C9DDC0ED96CC15606preparation-assessments-v3.8.json
      /83/release_status      		Historical; current review incomplete
      H51-C15F8B9DC8DC7F13B9B875C1preparation-assessments-v3.8.json
      /83/market_status/status      		Historical; current review incomplete
      H51-CC9338E168AFDB726F9EFE34preparation-assessments-v3.8.json
      /83/market_status/basis      		Historical; current review incomplete
      H51-79C461C7FDBFBFCC803E3E2Fpreparation-assessments-v3.8.json
      /83/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-D415A7D34C531471B554B33Epreparation-assessments-v3.8.json
      /83/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-C0EF4D2FFE697E8FBF545D13preparation-assessments-v3.8.json
      /83/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-5C4496279CE362CD9152F5AFpreparation-assessments-v3.8.json
      /83/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-923BE927886007FDA20AECAApreparation-assessments-v3.8.json
      /83/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-FCE8431F77476A07603AC219preparation-assessments-v3.8.json
      /83/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-AAD68AF1922069E54ED7F12Cpreparation-assessments-v3.8.json
      /83/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-2F2ECC7F2B5774B615471AFApreparation-assessments-v3.8.json
      /83/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-2FDE06ACDB7227D7C84A0FBDpreparation-assessments-v3.8.json
      /83/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-AB5F1B9598984F6850BACB94preparation-assessments-v3.8.json
      /83/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-154B378A6AFDF07B537EE7F8preparation-assessments-v3.8.json
      /83/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-7498EF0A074442B245877210preparation-assessments-v3.8.json
      /83/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-22FA7FBE2F0CA069BF14460Dpreparation-assessments-v3.8.json
      /83/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-550EED751EA0ED17D8158894preparation-assessments-v3.8.json
      /83/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-56252B493D39A8FC9EB663B2preparation-assessments-v3.8.json
      /83/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-29243931C76AA0E06BBD63BFpreparation-assessments-v3.8.json
      /83/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-018854A1832C33006D6EC7E8preparation-assessments-v3.8.json
      /83/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-7904A78EB51A4D58B1A6D66Epreparation-assessments-v3.8.json
      /83/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-D06280C65333C4A19CB0EF0Fpreparation-assessments-v3.8.json
      /83/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-A42FAFAC6BDB6F66D4BC160Epreparation-assessments-v3.8.json
      /83/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-536480C5B860FF9D306D926Fpreparation-assessments-v3.8.json
      /83/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-B3B4CBD0C03D72913E3E424Bpreparation-assessments-v3.8.json
      /83/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-0484553FEC8ED39E504835E0preparation-assessments-v3.8.json
      /83/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-E9C685B019A5EC75F99501EEpreparation-assessments-v3.8.json
      /83/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-770931D8C0FA0C41AB54145Cpreparation-assessments-v3.8.json
      /83/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-A97356075F2EB8EEE0D3D3D7preparation-assessments-v3.8.json
      /83/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-69945699737EFD769FC3D49Cpreparation-assessments-v3.8.json
      /83/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-DAA9FC1B3DB5439D95374BEDpreparation-assessments-v3.8.json
      /83/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-FE41037F7B055BD2C3572708preparation-assessments-v3.8.json
      /83/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-54DE6F8F6D11060778B253F0preparation-assessments-v3.8.json
      /83/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-6E30F75BE94E6FA679CFE3C7preparation-assessments-v3.8.json
      /83/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-C41A5EAF3AF4BF73D2E1056Bpreparation-assessments-v3.8.json
      /83/route_presence/structured_dilution      		Historical; current review incomplete
      H51-7B8E11D0EA032EEC204D43D6preparation-assessments-v3.8.json
      /83/route_presence/iv_push      		Historical; current review incomplete
      H51-9BBB16735E5FC5B42008B976preparation-assessments-v3.8.json
      /83/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-41AB8FCDFD8C68CD91FA4796preparation-assessments-v3.8.json
      /83/route_presence/pediatric_source      		Historical; current review incomplete
      H51-3527F93E8BABA1A716D40C97preparation-assessments-v3.8.json
      /83/route_presence/neonatal_source      		Historical; current review incomplete
      H51-7E93CDCF55AAD06866FE070Cpreparation-assessments-v3.8.json
      /83/legacy_reference/status      		Historical; current review incomplete
      H51-21583C1717AEC992EFDD0B18preparation-assessments-v3.8.json
      /83/label_resolution/status      		Historical; current review incomplete
      H51-42817FEFF23E053234E4F9A9preparation-assessments-v3.8.json
      /83/source_files/0      		Historical; current review incomplete
      H51-23A141B29332816DD717E52Bpreparation-assessments-v3.8.json
      /83/source_files/1      		Historical; current review incomplete
      H51-A26C9FE66FD0307CAE131B53preparation-assessments-v3.8.json
      /83/source_files/2      		Historical; current review incomplete
      H51-FFCEC7BF756F62443CF1956Apreparation-assessments-v3.8.json
      /83/source_files/3      		Historical; current review incomplete
      H51-5FE0050948C02126A5D77558preparation-assessments-v3.8.json
      /83/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top